A detailed history of Metis Global Partners, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Metis Global Partners, LLC holds 5,254 shares of REGN stock, worth $5.48 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
5,254
Previous 5,233 0.4%
Holding current value
$5.48 Million
Previous $5.04 Million 9.65%
% of portfolio
0.19%
Previous 0.19%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

BUY
$883.2 - $1071.19 $18,547 - $22,494
21 Added 0.4%
5,254 $5.52 Million
Q1 2024

May 06, 2024

BUY
$902.69 - $993.35 $6,318 - $6,953
7 Added 0.13%
5,233 $5.04 Million
Q4 2023

Feb 06, 2024

SELL
$775.18 - $881.7 $189,143 - $215,134
-244 Reduced 4.46%
5,226 $4.59 Million
Q3 2023

Nov 07, 2023

BUY
$692.45 - $844.37 $480,560 - $585,992
694 Added 14.53%
5,470 $4.5 Million
Q2 2023

Aug 07, 2023

BUY
$700.03 - $830.35 $58,102 - $68,919
83 Added 1.77%
4,776 $3.43 Million
Q1 2023

May 08, 2023

BUY
$680.49 - $826.97 $408,294 - $496,182
600 Added 14.66%
4,693 $3.86 Million
Q4 2022

Feb 07, 2023

BUY
$705.89 - $766.39 $804,008 - $872,918
1,139 Added 38.56%
4,093 $2.95 Million
Q3 2022

Nov 08, 2022

BUY
$573.97 - $724.32 $56,249 - $70,983
98 Added 3.43%
2,954 $2.03 Million
Q2 2022

Aug 08, 2022

BUY
$548.35 - $738.84 $432,099 - $582,205
788 Added 38.1%
2,856 $1.69 Million
Q1 2022

May 03, 2022

BUY
$595.12 - $698.43 $455,266 - $534,298
765 Added 58.71%
2,068 $1.44 Million
Q4 2021

Feb 11, 2022

BUY
$543.48 - $670.97 $708,154 - $874,273
1,303 New
1,303 $822,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $112B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Metis Global Partners, LLC Portfolio

Follow Metis Global Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metis Global Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Metis Global Partners, LLC with notifications on news.